Isis Pharmaceuticals Inc Announces Positive Phase 1 Data On Three Drugs In Development To Treat Metabolic Disorders

Friday, 7 Dec 2012 08:00am EST 

Isis Pharmaceuticals Inc announced positive results from Phase 1 studies of three drugs, ISIS-PTP1BRx, ISIS-GCGRRx and ISIS-GCCRRx, in development to treat metabolic disorders, including type 2 diabetes. In all three Phase 1 studies, the drugs were safe and well tolerated with early encouraging data that supports the mechanism of each drug. All three drugs are part of Isis' metabolic franchise and are designed to act through distinct mechanisms to improve insulin sensitivity and/or reduce glucose production. 

Company Quote

0.52 +1.72%
11 Jul 2014